Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04957550 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis

StatusActive, Not Recruiting
PhasePhase 3
Started2021-08-30
View on ClinicalTrials.gov ↗
This study is a phase 3 study,to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active psoriatic arthritis.

Amendment record

Amended 3 times since 2021-07-05; most recent filed 2026-08-27. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-08-27
Amendment Enrolling by Invitation→Active, Not Recruiting Study Status, Study Design v3
2023-02-07
Amendment Recruiting→Enrolling by Invitation Study Status, Contacts/Locations, IPDSharing v2
2021-11-08
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
2021-07-05
Original filing
Trial Details
NCT Number NCT04957550
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Psoriatic Arthritis
Enrollment 418 participants
Start Date 2021-08-30
Primary Completion 2026-12-13 (estimated)
Study Completion 2026-12-13 (estimated)
Updated on ClinicalTrials.gov 2026-08-28